Recent relevant Xconomy coverage:
Can AI Tools, $76M Lead BlackThorn to Targeted Psych Drugs?
Alector IPO Banks $176M to Test Alzheimer’s Drugs in Clinical Trials
With $2M Seed, Perlstein Lab Tests Unorthodox Rare-Disease Plan
3 – 4:00pm | Registration & Networking |
4 – 4:30pm | Spinal Cord Injury Therapies Step ForwardEthan Perlstein – Chief Scientific Officer, Christopher & Dana Reeve Foundation Explore the cutting-edge research that could become new therapies for spinal cord injuries and other traumatic neurological damage. |
4:30 – 5:00pm | AI Makes Headway Finding New Depression DrugsJane Tiller – Chief Medical Officer, BlackThorn Therapeutics Depression is a particularly challenging area for drug hunters, but BlackThorn Therapeutics says artificial intelligence, brain imaging, and other tools give it an edge finding and developing new medicines. |
5 – 5:30pm | An Immunotherapy Approach to Alzheimer’sStephanie Yonker – Vice President of Legal, Alector Does the immune system hold the key to understanding and treating Alzheimer’s disease? Alector is developing a drug that engages an immune cell in the brain to address neurodegeneration. |
5:30 – 6:30pm | Networking ReceptionDrinks & hors d’oeuvres |
Schedule is subject to change.